Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusettes (C.N.K.).
Ann Intern Med. 2022 Jun;175(6):892-894. doi: 10.7326/M22-1026. Epub 2022 Apr 12.
On 8 December 2021, the U.S. Food and Drug Administration issued an emergency use authorization for AstraZeneca's Evusheld (tixagevimab copackaged with cilgavimab, administered as concomitant injections) for the prevention of COVID-19 in those who are moderately to severely compromised, are aged 12 years or older, and weigh more than 40 kg. This commentary discusses current appropriate use of this important preventive intervention.
2021 年 12 月 8 日，美国食品和药物管理局发布了阿斯利康 Evusheld（替沙格韦单抗与西加韦单抗联合包装，作为同时注射给药）的紧急使用授权，用于预防中度至重度免疫功能低下者、12 岁及以上且体重超过 40 公斤的人群感染 COVID-19。本评论讨论了这一重要预防干预措施的当前合理使用。
